HC Wainwright Issues Optimistic Forecast for IPSC Earnings

Century Therapeutics, Inc. (NASDAQ:IPSC) – Research analysts at HC Wainwright raised their Q2 2026 earnings per share estimates for Century Therapeutics in a research report issued on Tuesday, May 19th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($0.11) per share for the quarter, up from their previous estimate of ($0.21). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Century Therapeutics’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Century Therapeutics’ Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.45) EPS, Q1 2027 earnings at ($0.12) EPS, Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.13) EPS, Q4 2027 earnings at ($0.13) EPS and FY2027 earnings at ($0.49) EPS.

Several other analysts have also recently commented on the company. Wall Street Zen cut Century Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Century Therapeutics in a report on Monday, April 6th. Zacks Research cut Century Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, March 12th. Leerink Partners set a $2.00 target price on Century Therapeutics and gave the company a “market perform” rating in a report on Friday, March 13th. Finally, TD Cowen initiated coverage on Century Therapeutics in a report on Wednesday, February 25th. They issued a “buy” rating on the stock. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $3.67.

Century Therapeutics Trading Up 6.1%

NASDAQ:IPSC opened at $2.25 on Thursday. The stock has a market cap of $405.79 million, a P/E ratio of -1.97 and a beta of 1.55. The stock’s 50-day moving average is $2.31 and its 200-day moving average is $1.69. Century Therapeutics has a 1-year low of $0.44 and a 1-year high of $3.04.

Century Therapeutics (NASDAQ:IPSC) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04.

Hedge Funds Weigh In On Century Therapeutics

Several institutional investors have recently added to or reduced their stakes in IPSC. Prudential Financial Inc. acquired a new position in Century Therapeutics in the second quarter valued at approximately $25,000. Bank of New York Mellon Corp acquired a new position in Century Therapeutics in the first quarter valued at approximately $29,000. Qube Research & Technologies Ltd acquired a new position in Century Therapeutics in the second quarter valued at approximately $38,000. Quadrant Private Wealth Management LLC lifted its stake in Century Therapeutics by 31.0% in the first quarter. Quadrant Private Wealth Management LLC now owns 20,022 shares of the company’s stock valued at $45,000 after buying an additional 4,736 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in Century Therapeutics in the second quarter valued at approximately $51,000. 50.20% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Century Therapeutics

In other Century Therapeutics news, insider Gregory Russotti sold 10,076 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $2.55, for a total value of $25,693.80. Following the transaction, the insider directly owned 515,427 shares of the company’s stock, valued at approximately $1,314,338.85. The trade was a 1.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 17,862 shares of company stock valued at $45,488 over the last quarter. 4.37% of the stock is currently owned by insiders.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.